ID: ALA3817887

Max Phase: Preclinical

Molecular Formula: C32H28F2N3O5P

Molecular Weight: 603.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1ccc(C(C/C=C/c2ccccc2)(Cc2ccc(C(F)(F)P(=O)(O)O)cc2)n2nnc3ccccc32)cc1

Standard InChI:  InChI=1S/C32H28F2N3O5P/c1-42-30(38)25-15-19-26(20-16-25)31(21-7-10-23-8-3-2-4-9-23,37-29-12-6-5-11-28(29)35-36-37)22-24-13-17-27(18-14-24)32(33,34)43(39,40)41/h2-20H,21-22H2,1H3,(H2,39,40,41)/b10-7+

Standard InChI Key:  GWWTUJWRRCTCSI-JXMROGBWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 603.56

Molecular Weight (Monoisotopic): 603.1735

AlogP: 6.53

#Rotatable Bonds: 10

Polar Surface Area: 114.54

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 0.74

CX Basic pKa: 0.13

CX LogP: 6.37

CX LogD: 4.22

Aromatic Rings: 5

Heavy Atoms: 43

QED Weighted: 0.14

Np Likeness Score: -0.46

References

1. Li X, Wang L, Shi D..  (2016)  The design strategy of selective PTP1B inhibitors over TCPTP.,  24  (16): [PMID:27353889] [10.1016/j.bmc.2016.06.035]

2. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source

Source(1):

• Scientific Literature